{"name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","slug":"jiangsu-hansoh-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"jiangsuhansoh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"ESPO","genericName":"ESPO","slug":"espo","indication":"Other","status":"marketed"},{"name":"HS-10380","genericName":"HS-10380","slug":"hs-10380","indication":"Other","status":"phase_1"},{"name":"Drug： Rosuvastatin","genericName":"Drug： Rosuvastatin","slug":"drug-rosuvastatin","indication":"Other","status":"phase_1"},{"name":"HS-10353","genericName":"HS-10353","slug":"hs-10353","indication":"Other","status":"phase_1"},{"name":"HS-10360","genericName":"HS-10360","slug":"hs-10360","indication":"Other","status":"phase_1"},{"name":"HS-10383","genericName":"HS-10383","slug":"hs-10383","indication":"Other","status":"phase_2"},{"name":"HS-10542 Low Dose","genericName":"HS-10542 Low Dose","slug":"hs-10542-low-dose","indication":"null","status":"phase_2"},{"name":"Placebo to match PEG-Tα1","genericName":"Placebo to match PEG-Tα1","slug":"placebo-to-match-peg-t-1","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"HS-20094","genericName":"HS-20094","slug":"hs-20094","indication":"Oncology indication (specific indication not publicly disclosed)","status":"phase_3"},{"name":"HS-10234","genericName":"HS-10234","slug":"hs-10234","indication":"FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)","status":"phase_3"},{"name":"HS-10241+ Almonertinib","genericName":"HS-10241+ Almonertinib","slug":"hs-10241-almonertinib","indication":"Non-small cell lung cancer with EGFR mutations (Phase 3 development)","status":"phase_3"},{"name":"HS-10296","genericName":"HS-10296","slug":"hs-10296","indication":"FGFR-altered solid tumors","status":"phase_3"},{"name":"Pemetrexed + Cisplatin /Carboplatin","genericName":"Pemetrexed + Cisplatin /Carboplatin","slug":"pemetrexed-cisplatin-carboplatin","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Xgeva®","genericName":"Xgeva®","slug":"xgeva","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"PEX168(100µg)","genericName":"PEX168(100µg)","slug":"pex168-100-g","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"PEX168(200µg)","genericName":"PEX168(200µg)","slug":"pex168-200-g","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"PEG-Tα1","genericName":"PEG-Tα1","slug":"peg-t-1","indication":"Chronic hepatitis B","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"pegol-Sihematide","genericName":"pegol-Sihematide","slug":"pegol-sihematide","indication":"Anemia associated with chronic kidney disease (CKD)","status":"phase_3"}]}],"pipeline":[{"name":"ESPO","genericName":"ESPO","slug":"espo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10380","genericName":"HS-10380","slug":"hs-10380","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-20094","genericName":"HS-20094","slug":"hs-20094","phase":"phase_3","mechanism":"HS-20094 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival pathways.","indications":["Oncology indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"Drug： Rosuvastatin","genericName":"Drug： Rosuvastatin","slug":"drug-rosuvastatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10234","genericName":"HS-10234","slug":"hs-10234","phase":"phase_3","mechanism":"HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (including cholangiocarcinoma and other FGFR-driven cancers)"],"catalyst":""},{"name":"HS-10241+ Almonertinib","genericName":"HS-10241+ Almonertinib","slug":"hs-10241-almonertinib","phase":"phase_3","mechanism":"HS-10241 is a third-generation EGFR tyrosine kinase inhibitor designed to target EGFR mutations including common and uncommon variants, often combined with almonertinib (a third-generation EGFR-TKI) to enhance efficacy against resistant lung cancers.","indications":["Non-small cell lung cancer with EGFR mutations (Phase 3 development)"],"catalyst":""},{"name":"HS-10296","genericName":"HS-10296","slug":"hs-10296","phase":"phase_3","mechanism":"HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors","Urothelial carcinoma with FGFR alterations"],"catalyst":""},{"name":"HS-10353","genericName":"HS-10353","slug":"hs-10353","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10360","genericName":"HS-10360","slug":"hs-10360","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10383","genericName":"HS-10383","slug":"hs-10383","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HS-10542 Low Dose","genericName":"HS-10542 Low Dose","slug":"hs-10542-low-dose","phase":"phase_2","mechanism":"HS-10542 Low Dose is a small molecule drug that targets the molecular target.","indications":["null"],"catalyst":""},{"name":"PEG-Tα1","genericName":"PEG-Tα1","slug":"peg-t-1","phase":"phase_3","mechanism":"PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation.","indications":["Chronic hepatitis B","Chronic hepatitis C","Immunodeficiency states"],"catalyst":""},{"name":"PEX168(100µg)","genericName":"PEX168(100µg)","slug":"pex168-100-g","phase":"phase_3","mechanism":"PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"PEX168(200µg)","genericName":"PEX168(200µg)","slug":"pex168-200-g","phase":"phase_3","mechanism":"PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Pemetrexed + Cisplatin /Carboplatin","genericName":"Pemetrexed + Cisplatin /Carboplatin","slug":"pemetrexed-cisplatin-carboplatin","phase":"phase_3","mechanism":"Pemetrexed is a folate antagonist that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to cell death in rapidly dividing cancer cells. Cisplatin and Carboplatin are platinum-based chemotherapeutic agents that induce DNA crosslinks, causing cell death.","indications":["Non-small cell lung cancer","Mesothelioma"],"catalyst":""},{"name":"Placebo to match PEG-Tα1","genericName":"Placebo to match PEG-Tα1","slug":"placebo-to-match-peg-t-1","phase":"phase_3","mechanism":"This is a placebo control formulation designed to match the appearance and administration characteristics of PEG-Tα1 (pegylated thymosin alpha 1) for blinded clinical trial purposes.","indications":[],"catalyst":""},{"name":"Xgeva®","genericName":"Xgeva®","slug":"xgeva","phase":"marketed","mechanism":"Xgeva (denosumab) is a monoclonal antibody that inhibits RANKL, preventing osteoclast formation and bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of giant cell tumor of bone","Prevention of bone loss in patients with hormone-responsive breast cancer receiving aromatase inhibitors"],"catalyst":""},{"name":"pegol-Sihematide","genericName":"pegol-Sihematide","slug":"pegol-sihematide","phase":"phase_3","mechanism":"Pegol-sihematide is a long-acting erythropoiesis-stimulating agent that promotes red blood cell production.","indications":["Anemia associated with chronic kidney disease (CKD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOWmdoSVZTdVhrc3VVWXlRWHdpT2l0Y3ZYSDBld0V5VlEwX1lEenNkNlBBMEI0X19WVVYxdGFuOWY3VzlLek5zbXBmVGVZMFFHamp5bFB0dmctLWs2RTRUQVM3eXFlLURMMW1kcUdvUllvUDVqRjJQR3ppRzI0SXRsZExxSGdiSFNaeGJpOGpqXzIwSEFUQ0dxdko5RFBUcWJUdHNzaWFiM2FaQ2lGdlBrVTV2V2RVaXgwRDNuX01ZdmFaQ05PNDZqdjRrT2hYaWxyZFk4d1FNUFdkQTlUYUZEU2sxaGh5ZkQxeTlTQ1dsQm1HQUhnX2JHTWE2Yw?oc=5","date":"2026-03-05","type":"trial","source":"Barchart.com","summary":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Domain | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-17","type":"pipeline","source":"ET Pharma","summary":"Glenmark secures multi-regional rights for Hansoh’s lung cancer drug Aumolertinib - ET Pharma","headline":"Glenmark secures multi-regional rights for Hansoh’s lung cancer drug Aumolertinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOUUNRSkdwQWx6ODdvX1l6Q1JWWG11QTRzOWNlRHR2ejlsOEhLYjFVcHRtMVRPMFpEMHNyOUlqbEdrMnpfQUN2cklldkFsRjd5N18yWmVtZWxxTDBneDVyUVRpcnFoUXVHMTJERVB5cm0ydFpqU0Q1bUpwQ0JvWGRsZHctSFhDWXg3QkZja2liUDhyNzNPRlkzMkd1SXFPLW5IMTVNalZiSGptMmU4?oc=5","date":"2025-12-17","type":"pipeline","source":"Equitypandit","summary":"Glenmark Unit Signs Exclusive NSCLC Drug Pact with Hansoh Pharma; Shares Drop 1% - Equitypandit","headline":"Glenmark Unit Signs Exclusive NSCLC Drug Pact with Hansoh Pharma; Shares Drop 1%","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"pipeline","source":"CNBC TV18","summary":"Glenmark unit signs exclusive licensing pact with Hansoh Pharma for NSCLC drug Aumolertinib - CNBC TV18","headline":"Glenmark unit signs exclusive licensing pact with Hansoh Pharma for NSCLC drug Aumolertinib - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBGV3lsb3FXNDdYUDF2SjFLRHlwYWswdEdoMG5BRUpOeTFjclBMRjNIWjljUE9XVFUxV0lEeDBxdV9iZy15S0trYWdDTWhuQ2xob1VJLVBPWUdLNHY2RU1nTmtLaElIWkZhcWIyYlJ1bUYzRHlaeDFJZE8wRklLZw?oc=5","date":"2025-10-21","type":"pipeline","source":"China Daily","summary":"Pharma sector transforms for growth - China Daily","headline":"Pharma sector transforms for growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNUnl2bEw4NEpoSnVqMlFSbkFuSkN3OHp6VzhHMWZ4NzhuMVBzZHIxbm9SRVlmeEw3OUp6SklTU1MzTkJzNXdFNlFZUEZ3X0dSNGl5bkRzZUZnVGljNlRPYjdsY3FGT0RTMW9CVWhsNURzYUp6VjVJajlKUDM0QV9qYkt2aUdiM1VlNTVEcm14cjBPVnF6R1dobDJWYU8xQm5iRmFPS25JNWRhRlNKaVBNemlWbUJVOWxMNU1yQTln0gG-AUFVX3lxTE5WUTM4bU51MDdFUUM5emptLTlCeUxvV3hYZjNmdktEdkVDU2czNk84VnBsc08tOFZWcVp3a0w5anlIT1kxTXctRW14MEtmeWY5R3FoQkJqY1pBcnJhRVJuQlVtcmxPZ21HdkNWdXA5c3dXU2hLQlQ4X2g3UkJVZHFwXzlHSHdHVW9USHhoVmpRN0cybGxDaXdIQkN6bWpqczNBdFk1SkFZcm5sMktZQ1NVODVWOGJzSmZmMTJlSFE?oc=5","date":"2025-08-18","type":"earnings","source":"South China Morning Post","summary":"Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits - South China Morning Post","headline":"Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPLUN3dEIwYkdDQXIxUmNyX3ZUN2ZwcWFBMllZbHpUc2hheFdta0VlSHYySVMtZmFmRjIzdDNWamdXajNWdnFQSkp5VzJUU1FYNXBsZjlldFFzT21jZThfXzlNUWRjcW9ZSU1jVXlwVU9ZeUUwaEJtUTNuZkZhYk9lZUpwem1YM183SF9XUlBxcDlvYlFmQjl1em5xZ3BzVE5scFR5cUc0bFl5UUg2ZmhuM21lVkNzOTNySWJxRVZlS0FmNGtQU1hkck56OWhpZmRQU255OHdTZjVPQloyX3k4YnJTdzlUWFU0MFN2WFVPZjdWbDcyZ3R2Q2w1SVRZbVhPWXR3M1dYdWRVdm5MMEhLc2hMZ3UweG8?oc=5","date":"2025-06-02","type":"deal","source":"Citeline News & Insights","summary":"Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations - Citeline News & Insights","headline":"Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNc1dhZldSbUNQQWdIdFRpaHc3RzM1N2xVOE4xNFZXU2psOWN0aHJkYVU0a1h1ZGplaGI3SDVUd0VpMDlSUm45UkhTRTZIY053a0N1SzBvaEphODRFZXVsaGxZWTFQNW1wVjBwcFNmNk9yRzc3bHgwUDdKcUdpeWhGa2prVi1OdnpydGFJc1VXcVl5MDhiNWUyc1ByV0ZRaGRTVmRhN1NSQ2NtYXhVX1JKRA?oc=5","date":"2025-05-23","type":"pipeline","source":"Bloomberg.com","summary":"Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading - Bloomberg.com","headline":"Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNQ1B2a3ZQVHB2TmpCUEJxeHBvQjhJWmZ5N1V0dUZBclJTSDNzc3VwZ0VTeTI5cEtJTkd1Uk1fVE1wdENQdXZ1X3FXSGFGLWpvTWVHTmFTMjJFN3gzaE0xajhPbW5iS3pRMUdjVnJJa296Vjc3LWRCaGNUQVQ0WVk3VVVQamxRZ204anc?oc=5","date":"2024-08-30","type":"patent","source":"BioWorld News","summary":"Hansoh Pharma patents new GLP-1R agonists - BioWorld News","headline":"Hansoh Pharma patents new GLP-1R agonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNY0dtN0UxZFpJaWc2X0UtMzJ6dzc4Yl9zVzV2b2x3eWlweWxGdFNIU3RoNEZpRTVRM1hoc05aWHdyMW1XUEQyQTk5cWlrWWE4SU5DYUwwMWtkVjc1b0ZqYTBROTlxZzNMRjYwdUstbVVUM3ZMZUQ3S2xqMGpDQVhmUkhkWEM2akpYMVlMLU1mY21aLWcyekxtN1FkQUNiRDgxUm40RDFjczRReXpfNHczOGdqSXFsTHJEWXFBT2g5dnE3R1IyYnBnNFFLMEVvbjVlTktwak1ZUmpLc241VUpIb1hoNXVNUjNyckhQS0NWcU1JTDRfc0RnMmRMeXQ4NThIRDNENjhLQTBldw?oc=5","date":"2022-05-03","type":"deal","source":"Business Wire","summary":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China - Business Wire","headline":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater Chin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQOGZJV0xySmNRWmo3M255cGdnNFBLaHZ6dGlCRmU4OEJsc2Z4aFJtazRmNkZzTEN1VXFZdXZMZUdSTG5iT25FT3QwT1FXeHpSbFhUeFVyRG45LXBPME05NGNiN0lmMzU5QkkzaXNBWXBGNWdPVjhRSlZRNzhabkM5ZjVadUEtV0o3RVMzdzhGNEhOaDd0bDZmd2Q0eHpjUEp5YV9OSDdlTVdGaDlLN1FwTjZNVlhsbnZoVzdpSFZucjVhQlktMm9tRzhhSll2ZXhlRS10MVQ1TjJyYzFKWmQ1YWhSajRCRFZtSVFYVXFvU3Z0LTZNVWw1eHBKWGNsYlNEN1RaMEtfQXRmOE1XdC16T082YksyRUI2TzljbEJBSGFYLW5zWWtQYkplZHhoTW1wa1FBY0VPWlgwdEhNWUNwUmpZcU9Td0k?oc=5","date":"2021-10-12","type":"pipeline","source":"GlobeNewswire","summary":"Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing - GlobeNewswire","headline":"Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing","sentiment":"neutral"}],"patents":[],"drugCount":18,"phaseCounts":{"marketed":2,"phase_1":4,"phase_3":10,"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}